Corden Pharma - A Full-Service CDMO

Background

Overview

Corden Pharma is a global Contract Development and Manufacturing Organization (CDMO) specializing in the comprehensive development and manufacturing of pharmaceutical products. Established in 2006, the company operates 11 cGMP facilities across Europe and the United States, employing between 1,000 and 5,000 professionals. Corden Pharma supports pharmaceutical and biotechnology innovators with complex modalities organized into six technology platforms:

• Peptides

• Lipids & Carbohydrates

• Oligonucleotides

• Injectables

• Highly Potent & Oncology

• Small Molecules

The company offers a range of services, including API and excipient development, drug product manufacturing, and specialized modalities. Corden Pharma is known for its expertise in lipid nanoparticles, high-purity synthetic compounds, and sterile formulations. With a mission to enhance patient well-being through high-quality products, Corden Pharma aims to be the most trusted CDMO by delivering flexible and transparent solutions. The company has achieved significant financial growth, with record sales exceeding €870 million in 2022, and continues to invest in innovative drug delivery systems and complex active pharmaceutical ingredients.

Key Strategic Focus

Core Objectives

Corden Pharma's strategic focus centers on providing end-to-end solutions for pharmaceutical and biotechnology companies, encompassing the entire drug development lifecycle from early-phase development to commercialization. The company emphasizes flexibility, transparency, and a commitment to quality, aiming to be the most trusted partner in the CDMO sector.

Areas of Specialization

Corden Pharma specializes in six technology platforms:

• Peptides: Development and manufacturing of peptide APIs and drug products.

• Lipids & Carbohydrates: Production of lipid excipients and carbohydrate-based compounds.

• Oligonucleotides: Synthesis and manufacturing of oligonucleotide-based therapies.

• Injectables: Formulation and production of sterile injectable drug products.

• Highly Potent & Oncology: Handling of highly potent compounds and oncology drug products.

• Small Molecules: Synthesis and manufacturing of small molecule APIs and drug products.

Key Technologies Utilized

Corden Pharma employs advanced technologies across its platforms, including:

• Lipid Nanoparticles (LNPs): Utilized in the development of mRNA-based therapies.

• High-Purity Synthetic Compounds: Ensuring the production of high-quality APIs.

• Sterile Formulations: Advanced techniques for aseptic processing and fill-finish operations.

Primary Markets Targeted

The company serves a global clientele, including pharmaceutical and biotechnology companies, with a focus on complex modalities such as peptides, oligonucleotides, and highly potent compounds. Corden Pharma's services cater to both early-phase development and large-scale commercial manufacturing.

Financials and Funding

Funding History

Corden Pharma was acquired by the private equity firm Astorg in 2022, which has supported strategic growth initiatives, including capacity expansions for lipid nanoparticle (LNP) production critical for mRNA vaccines.

Total Funds Raised

Specific details regarding the total funds raised by Corden Pharma are not publicly disclosed.

Recent Funding Rounds

In 2024, Corden Pharma announced a €900 million investment to expand its peptide technology platform over the next three years. This expansion includes new facilities and upgrades in the U.S. and Europe to meet the rising demand for peptide-based medications.

Notable Investors

Astorg, a private equity firm, is a notable investor following its acquisition of Corden Pharma in 2022.

Intended Utilization of Capital

The €900 million investment is allocated for:

• Construction of a new large-scale manufacturing facility at the Corden Pharma Colorado site.

• Expansion of existing facilities in the U.S. and Europe.

• Enhancement of capabilities to support peptide-based drug development.

Pipeline Development

Key Pipeline Candidates

Corden Pharma's pipeline includes:

• Peptide-Based Therapies: Development and manufacturing of GLP-1 agonists for diabetes and obesity treatments.

• Highly Potent Compounds: Oncology drug products requiring specialized handling and manufacturing.

Stages of Clinical Trials or Product Development

Specific details regarding the stages of clinical trials or product development for individual pipeline candidates are not publicly disclosed.

Target Conditions

The company's pipeline targets conditions such as:

• Diabetes

• Obesity

• Various cancers

Relevant Timelines for Anticipated Milestones

The first phase of the Boulder site expansion is planned to come online in 2026, with full completion in 2028.

Technological Platform and Innovation

Proprietary Technologies

Corden Pharma's proprietary technologies include:

• Lipid Nanoparticles (LNPs): Critical for mRNA vaccine development.

• High-Purity Synthetic Compounds: Ensuring the production of high-quality APIs.

• Sterile Formulations: Advanced techniques for aseptic processing and fill-finish operations.

Significant Scientific Methods

The company employs:

• Tag-Assisted Peptide Synthesis (TAPS): A continuous liquid-phase process for peptide synthesis.

• Advanced Aseptic Processing: For the production of sterile injectable drug products.

AI-Driven Capabilities

Specific details regarding AI-driven capabilities are not publicly disclosed.

Leadership Team

Key Executive Profiles

• Dr. Michael Quirmbach: President & CEO

• Professional Background:

• Served as Managing Director at Astorg.

• Extensive experience in the pharmaceutical industry.

• Contributions:

• Led the acquisition of Corden Pharma by Astorg in 2022.

• Spearheaded strategic growth initiatives, including capacity expansions for LNP production.

• Sven Hauptmann: Chief Operations Officer, Drug Product

• Professional Background:

• Held various leadership roles in pharmaceutical manufacturing.

• Contributions:

• Oversees drug product operations, ensuring compliance with global regulatory standards.

• Lee Newton: Chief Operations Officer, Drug Substance

• Professional Background:

• Extensive experience in pharmaceutical operations and supply chain management.

• Contributions:

• Manages drug substance operations, focusing on efficient and compliant manufacturing processes.

Leadership Changes

As of May 16, 2025, Swantje Thiering, Vice President and Global Head of Program Management, left the company.

Competitor Profile

Market Insights and Dynamics

The global CDMO market is experiencing robust growth, with projections indicating a compound annual growth rate (CAGR) of 7.3% from 2025 to 2034. This growth is driven by increasing demand for complex pharmaceutical products, including biologics and highly potent compounds.

Competitor Analysis

Key competitors in the CDMO sector include:

• Rottendorf Pharma: Specializes in the development and manufacturing of oral solid dosage forms.

• Recipharm: Offers a wide range of services, including drug development, manufacturing, and packaging.